Cargando…

Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series

Untreated opioid use disorder (OUD) in pregnancy may lead to adverse outcomes for the individual and fetus. Injectable opioid agonist therapy (iOAT) is the highest intensity treatment for severe refractory OUD currently available; however, research on perinatal administration is limited. We present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patricelli, Charissa J., Chai, Jessie, Gordon, Shanlea, Gouin, Isabelle J., Carter, Nicole, Stewart, Karly, Paquette, Vanessa, Urbanoski, Karen, Albert, Arianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417207/ https://www.ncbi.nlm.nih.gov/pubmed/37579103 http://dx.doi.org/10.1097/ADM.0000000000001152

Ejemplares similares

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report
por: Patricelli, Charissa J., et al.
Publicado: (2023)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

“It feels like I’m coming to a friend’s house”: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre)
por: Dobischok, Sophia, et al.
Publicado: (2023)

IOAT: an interactive tool for statistical analysis of omics data and clinical data
por: Wu, Lanlan, et al.
Publicado: (2021)

Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
por: Larney, Sarah, et al.
Publicado: (2018)

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
por: Thakrar, Ashish P., et al.
Publicado: (2023)

Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
por: Noroozi, Alireza, et al.
Publicado: (2023)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
por: Russell, Cayley, et al.
Publicado: (2022)

Perinatal Opioid Exposure Primes the Peripheral Immune System Toward Hyperreactivity
por: Newville, Jessie, et al.
Publicado: (2020)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
por: Kåberg, M., et al.
Publicado: (2022)

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.
por: Jones, Nicola, et al.
Publicado: (2022)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017
por: Aas, Christer Frode, et al.
Publicado: (2020)

Processing of oat: the impact on oat's cholesterol lowering effect
por: Grundy, Myriam M.-L., et al.
Publicado: (2018)

Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment
por: Arnet, Isabelle, et al.
Publicado: (2023)

PM287. Mixtures of opioid receptor agonists and cannabinoid receptor agonists: enhanced antinociception without abuse liability
por: France, Charles P, et al.
Publicado: (2016)

In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
por: Guillemyn, Karel, et al.
Publicado: (2012)

OATE Conference
por: Araki, Huzihiro, et al.
Publicado: (1985)

Wild Oats
Publicado: (1899)

Oat Meal
Publicado: (1891)

Oat Meal
Publicado: (1874)

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
por: Hu, S, et al.
Publicado: (2017)

To Be Oats or Not to Be? An Update on the Ongoing Debate on Oats for Patients With Celiac Disease
por: Spector Cohen, Inna, et al.
Publicado: (2019)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Commentary: To Be Oats or Not to Be? An Update on the Ongoing Debate on Oats for Patients With Celiac Disease
por: Fritz, Ronald D., et al.
Publicado: (2020)

Narrative Review on the Effects of Oat and Sprouted Oat Components on Blood Pressure
por: Liska, DeAnn J., et al.
Publicado: (2022)

Developmental outcomes with perinatal exposure (DOPE) to prescription opioids
por: Flores, Adrian, et al.
Publicado: (2023)

Sowing Wild Oats
Publicado: (1914)

Absorption and Elimination of Oat Avenanthramides in Humans after Acute Consumption of Oat Cookies
por: Zhang, Tianou, et al.
Publicado: (2017)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
por: Day, Nathaniel, et al.
Publicado: (2022)

Survey of T-2 and HT-2 toxins by LC–MS/MS in oats and oat products from European oat mills in 2005–2009
por: Pettersson, Hans, et al.
Publicado: (2011)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
por: Morin, Kristen A., et al.
Publicado: (2020)

Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease
por: Comino, Isabel, et al.
Publicado: (2011)

The Genetic Architecture of Milling Quality in Spring Oat Lines of the Collaborative Oat Research Enterprise
por: Esvelt Klos, Kathy, et al.
Publicado: (2021)

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.
por: Bharat, Chrianna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ifddib30co9i79ej6vrdbvpptv